Boris Kubuschok Selected Research

Boris Kubuschok Research Topics

Disease

16	Neoplasms (Cancer) 01/2017 - 05/2002
11	Testicular Neoplasms (Testicular Cancer) 07/2013 - 09/2002
6	Pancreatic Neoplasms (Pancreatic Cancer) 12/2012 - 05/2002
6	Breast Neoplasms (Breast Cancer) 09/2011 - 12/2003
4	Lymphoma (Lymphomas) 01/2017 - 11/2005
4	Adenocarcinoma 12/2012 - 04/2004
3	Autoimmune Diseases (Autoimmune Disease) 05/2016 - 01/2015
3	Multiple Myeloma 09/2015 - 07/2007
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 01/2017
2	Chronic Pancreatitis 07/2006 - 04/2004
2	Melanoma (Melanoma, Malignant) 11/2004 - 07/2004
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019
1	Systemic Mastocytosis 01/2019
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2017
1	Vasculitis (Vasculitides) 05/2016
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 05/2016
1	Giant Cell Arteritis (Horton Disease) 05/2016
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 09/2015
1	Paraproteinemias (Monoclonal Gammopathy) 01/2015
1	Aneuploidy (Aneuploid) 07/2013
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2009
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 09/2009
1	B-Cell Lymphoma (Lymphoma, B Cell) 09/2009
1	Monoclonal Gammopathy of Undetermined Significance 07/2007
1	Human Influenza (Influenza) 09/2006
1	Lymphatic Metastasis 07/2006
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 11/2005
1	Inflammation (Inflammations) 04/2004
1	Hepatocellular Carcinoma (Hepatoma) 09/2002

Drug/Important Bio-Agent (IBA)

18	AntigensIBA 01/2021 - 09/2002
7	Proteins (Proteins, Gene)FDA Link 01/2015 - 11/2004
7	VaccinesIBA 07/2013 - 09/2002
7	EpitopesIBA 09/2011 - 07/2004
6	Peptides (Polypeptides)IBA 09/2011 - 12/2003
5	Neoplasm Antigens (Tumor Antigens)IBA 12/2012 - 05/2002
4	Protein Subunit VaccinesIBA 11/2005 - 12/2003
3	ParaproteinsIBA 09/2015 - 07/2007
3	Complementary DNA (cDNA)IBA 09/2010 - 07/2006
3	Immunoglobulin G (IgG)IBA 09/2009 - 07/2006
3	SCP 1IBA 07/2006 - 09/2002
2	AutoantibodiesIBA 05/2016 - 07/2015
2	Cancer VaccinesIBA 12/2012 - 05/2002
2	Codon (Codons)IBA 12/2012 - 05/2002
2	AntibodiesIBA 09/2011 - 09/2009
2	Proto-Oncogene Proteins p21(ras)IBA 02/2006 - 05/2002
2	TESIBA 11/2005 - 09/2002
2	HLA-DR Antigens (HLA-DR)IBA 11/2004 - 07/2004
1	AutoantigensIBA 01/2021
1	Core Binding Factors (Core-Binding Factor)IBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2017
1	lamin CIBA 05/2016
1	ProgranulinsIBA 07/2015
1	Type I Tumor Necrosis Factor ReceptorsIBA 07/2015
1	Telomerase (Telomerase Reverse Transcriptase)IBA 07/2013
1	ISCOMATRIXIBA 07/2011
1	Messenger RNA (mRNA)IBA 09/2010
1	Protein Kinase C betaIBA 09/2009
1	SurvivinIBA 09/2009
1	Immunoglobulin A (IgA)IBA 07/2007
1	Insulin-Like PeptidesIBA 07/2007
1	tripeptidyl-peptidase 2IBA 07/2007
1	KinesinsIBA 07/2007
1	Inosine Monophosphate (IMP)IBA 09/2006
1	Gemcitabine FDA Link 07/2006
1	EnzymesIBA 02/2006
1	Oncogene Proteins (Oncogene Protein)IBA 02/2006
1	Estrogen ReceptorsIBA 02/2006
1	MucinsIBA 10/2005
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 04/2004
1	Phenylalanine (L-Phenylalanine)FDA Link 04/2004
1	HLA-A Antigens (HLA-A)IBA 12/2003
1	HLA-A*02:01 antigenIBA 12/2003

Therapy/Procedure

3	Therapeutics 01/2017 - 09/2010
3	Immunotherapy 07/2006 - 05/2002